VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 16, Issue 6, 2016, Pages 329-334.e1

  Siegel, David S ^a   Dimopoulos, Meletios ^b   Jagannath, Sundar ^c   Goldschmidt, Hartmut ^d   Durrant, Simon ^e   Kaufman, Jonathan L ^f   Leleu, Xavier ^g   Nagler, Arnon ^h   Offner, Fritz ⁱ   Graef, Thorsten ^j   Eid, Joseph E ^j   Houp, Jennifer ^j   Gause, Christine ^j   Vuocolo, Scott ^j   Anderson, Kenneth C ^k  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIV LILLE   (France)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j MERCK RESEARCH LABORATORIES   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Combination therapy; Efficacy; Histone deacetylase inhibitor; Proteasome inhibitor; Safety

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; CLINICAL TRIAL; DRUG RESISTANCE; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MULTIPLE MYELOMA; RECURRENCE; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961927110     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2016.02.042     Document Type: Article

References (21)

1. K.C. Anderson, R.A. Kyle, S.V. Rajkumar, A.K. Stewart, D. Weber, and P. Richardson Clinically relevant end points and new drug approvals for myeloma Leukemia 22 2008 231 239
2. S. Elkinson, and P.L. McCormack Pomalidomide: first global approval Drugs 73 2013 595 604
3. P.G. Richardson, D. Siegel, R. Baz, and et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Blood 121 2013 1961 1967
4. J.F. San Miguel, P.G. Richardson, A. Gunther, and et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma J Clin Oncol 31 2013 3696 3703
5. J.S. Miguel, K. Weisel, P. Moreau, and et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 1055 1066
6. P.G. Richardson, R.L. Schlossman, M. Alsina, and et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma Blood 122 2013 2331 2337
7. J.L. Thompson Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma Ann Pharmacother 47 2013 56 62
8. S. Jagannath, R. Vij, A.K. Stewart, and et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma Clin Lymphoma Myeloma Leuk 12 2012 310 318
9. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
10. J.W. Jeong, M.K. Bae, M.Y. Ahn, and et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation Cell 111 2002 709 720
11. P. Bali, M. Pranpat, J. Bradner, and et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 2005 26729 26734
12. C.S. Chen, S.C. Weng, P.H. Tseng, H.P. Lin, and C.S. Chen Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes J Biol Chem 280 2005 38879 38887
13. S.J. Haggarty, K.M. Koeller, J.C. Wong, C.M. Grozinger, and S.L. Schreiber Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc Natl Acad Sci U S A 100 2003 4389 4394
14. C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan, and et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A 101 2004 540 545
15. T. Hideshima, J.E. Bradner, J. Wong, and et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 2005 8567 8572
16. L. Santo, T. Hideshima, A.L. Kung, and et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 119 2012 2579 2589
17. H.M. Prince, M. Bishton, and S. Harrison The potential of histone deacetylase inhibitors for the treatment of multiple myeloma Leuk Lymphoma 49 2008 385 387
18. S.K. Kumar, J.H. Lee, J.J. Lahuerta, and et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
19. P.G. Richardson, P. Sonneveld, M.W. Schuster, and et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498
20. R.Z. Orlowski, A. Nagler, P. Sonneveld, and et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 2007 3892 3901
21. M. Dimopoulos, D.S. Siegel, S. Lonial, and et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicenter, randomised, double-blind study Lancet Oncol 14 2013 1129 1140